P411 Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

作者
Zsuzsanna Kürti,Mariann Rutka,Zsuzsanna Végh,Lóránt Gönczi,Klaudia Farkas,Barbara Dorottya Lovasz,Krisztina Barbara Gecse,Petra Anna Golovics,Balázs Szalay,Tamás Molnár,Peter Laszlo Lakatos
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:11 (suppl_1): S286-S286
标识
DOI:10.1093/ecco-jcc/jjx002.536
摘要

Background: Therapeutic drug monitoring (TDM) measuring drug trough levels (TL) and antidrug antibodies (ADA) may aid the therapeutic decision in patients with inflammatory bowel disease (IBD) who loose response to anti-TNF therapy. Our aim was to evaluate the frequency and predictive factors of loss of response to adalimumab therapy and the role of the therapeutic drug monitoring to predict the loss of response in adalimumab treated IBD patients. Methods: 112 IBD patients (with 214 TDM measurements, CD/UC 84/28, male/female 50/62, mean age CD/UC: 36/35 years, mean duration of adalimumab therapy CD/UC: 157.8/70.1 weeks) were enrolled in this consecutive cohort from two referral IBD centres in Hungary. Demographic data were comprehensively collected and a harmonized monitoring strategy was applied. Previous and current therapy, laboratory data and clinical activity at the time of the TL and ADA measurement were recorded. Patients were evaluated either at the time of suspected LOR or during follow-up. TDM measurements were done by commercial ELISA (LISA TRACKER, Theradiag, France). Results: Among 112 IBD patients, LOR/drug persistence was 25.9%/74.1%.The probability of ADA positivity and low TL (<4.0 μg/mL) was 12.1% and 17.8% in the first year and 17.3% and 29.5% and in the second year after start of adalimumab therapy in Kaplan-Meier analysis. Dose intensification was needed in 29.5% during the study period. There was an association between female gender, ADA positivity and LOR (female gender: p<0.001, OR: 7.770 CI95%: 2.483–24.315, ADA positivity: p=0.007 OR: 3.616 CI95%: 1.374–9.518)), while no other parameters, including TL was associated with LOR or dose intensification. Table 1. ADA and TL status in IBD patients treated with adalimumab Conclusions: Our results suggest that ADA development, low TL and need for dose intensification are frequent during adalimumab therapy and support the use of routine TDM assessment in IBD patients. Female gender, and ADA positivity were predictors of loss of response.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Felix发布了新的文献求助10
1秒前
1秒前
年轻烨霖发布了新的文献求助10
1秒前
天天向上发布了新的文献求助10
1秒前
zkb发布了新的文献求助30
2秒前
entscholar完成签到,获得积分10
3秒前
3秒前
4秒前
Owen的应助被强强采纳,获得10
4秒前
小蘑菇的应助被科研通管家采纳,获得10
4秒前
Owen的应助被科研通管家采纳,获得10
4秒前
所所的应助被科研通管家采纳,获得10
4秒前
大丑橘粑粑柑公主完成签到,获得积分10
4秒前
大个的应助被科研通管家采纳,获得10
4秒前
爆米花的应助被科研通管家采纳,获得10
4秒前
科研通AI2S的应助被科研通管家采纳,获得10
4秒前
追风少年的应助被科研通管家采纳,获得30
5秒前
5秒前
情怀的应助被科研通管家采纳,获得10
5秒前
情怀的应助被科研通管家采纳,获得10
5秒前
Lucas的应助被科研通管家采纳,获得10
5秒前
奔跑的应助被科研通管家采纳,获得10
5秒前
乐乐的应助被科研通管家采纳,获得10
5秒前
科研通AI65的应助被科研通管家采纳,获得10
5秒前
FashionBoy的应助被科研通管家采纳,获得10
6秒前
Lvy关注了科研通微信公众号
6秒前
NexusExplorer的应助被科研通管家采纳,获得10
6秒前
GPTea的应助被科研通管家采纳,获得20
6秒前
乐乐发布了新的文献求助10
6秒前
6秒前
6秒前
搜集达人的应助被科研通管家采纳,获得10
6秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
6秒前
田様的应助被科研通管家采纳,获得10
6秒前
yyyyy发布了新的文献求助10
6秒前
Owen的应助被科研通管家采纳,获得10
7秒前
7秒前
7秒前
yihuifa完成签到 ,获得积分0
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193599
求助须知:如何正确求助?哪些是违规求助? 9579723
关于积分的说明 21867157
捐赠科研通 7793198
什么是DOI,文献DOI怎么找? 3437314
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484193